https://scholars.lib.ntu.edu.tw/handle/123456789/468853
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Huang W.-T. | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHUNG-WU LIN | en_US |
dc.creator | Huang W.-T.;Kuo S.-H.;Cheng A.-L.;Chung-Wu Lin | - |
dc.date.accessioned | 2020-03-03T03:36:43Z | - |
dc.date.available | 2020-03-03T03:36:43Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0893-3952 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905504436&doi=10.1038%2fmodpathol.2013.229&partnerID=40&md5=17f24592c84a3305455c0388bd733691 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/468853 | - |
dc.description.abstract | Primary gastric diffuse large B-cell lymphomas may or may not have a concurrent component of mucosa-associated lymphoid tissue lymphoma. Diffuse large B-cell lymphoma/mucosa-associated lymphoid tissue lymphomas are often associated with Helicobacter pylori (H. pylori) infection, suggesting that the large cells are transformed from mucosa-associated lymphoid tissue lymphomas. In contrast, only limited data are available on the clinical and molecular features of pure gastric diffuse large B-cell lymphomas. In 102 pure gastric diffuse large B-cell lymphomas, we found H. pylori infection in 53% of the cases. H. pylori-positive gastric diffuse large B-cell lymphomas were more likely to present at an earlier stage (73% vs 52% at stage I/II, P=0.03), to achieve complete remission (75% vs 43%, P=0.001), and had a better 5-year disease-free survival rate (73% vs 29%, P<0.001) than H. pylori-negative gastric diffuse large B-cell lymphomas. Through genome-wide expression profiles of both miRNAs and mRNAs in nine H. pylori-positive and nine H. pylori-negative gastric diffuse large B-cell lymphomas, we identified inhibition of ZEB1 (zinc-finger E-box-binding homeobox 1) by miR-200 in H. pylori-positive gastric diffuse large B-cell lymphomas. ZEB1, a transcription factor for marginal zone B cells, can suppress BCL6, the master transcription factor for germinal center B cells. In 30 H. pylori-positive and 30 H. pylori-negative gastric diffuse large B-cell lymphomas, we confirmed that H. pylori-positive gastric diffuse large B-cell lymphomas had higher levels of miR-200 by qRT-PCR, and lower levels of ZEB1 and higher levels of BCL6 using immunohistochemistry. As BCL6 is a known predictor of a better prognosis in gastric diffuse large B-cell lymphomas, our data demonstrate that inhibition of ZEB1 by miR-200, with secondary increase in BCL6, is a molecular event that characterizes H. pylori-positive gastric diffuse large B-cell lymphomas with a less aggressive behavior. ? 2014 USCAP, Inc.. | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.ispartof | Modern Pathology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | messenger RNA; microRNA; microRNA 200; microRNA 200a; microRNA 200b; microRNA 200c; protein bcl 6; rituximab; transcription factor ZEB1; cyclophosphamide; doxorubicin; epirubicin; etoposide; microRNA 142 3p; microRNA 507; microRNA 513; microRNA 520e; microRNA 544; mitoxantrone; prednisolone; rituximab; unclassified drug; vincristine; antineoplastic agent; BCL6 protein, human; DNA binding protein; homeodomain protein; microRNA; MIRN200 microRNA, human; transcription factor; tumor marker; ZEB1 protein, human; adult; article; controlled study; disease free survival; event free survival; female; follow up; gastric diffuse large b cell lymphoma; gene expression; Helicobacter infection; histopathology; human; human tissue; immunohistochemistry; International Prognostic Index; large cell lymphoma; lymph node metastasis; major clinical study; male; outcome assessment; priority journal; protein blood level; quantitative analysis; remission; reverse transcription polymerase chain reaction; stomach lymphoma; survival rate; Article; B lymphocyte; cancer combination chemotherapy; cancer prognosis; cancer regression; cancer staging; cancer survival; disease association; genetic association; germinal center; large cell lymphoma; overall survival; stomach lymphoma; treatment response; chemistry; gene expression profiling; gene expression regulation; genetics; Helicobacter Infections; Helicobacter pylori; isolation and purification; Lymphoma, Large B-Cell, Diffuse; microbiology; middle aged; mortality; pathology; phenotype; real time polymerase chain reaction; Stomach Neoplasms; time; treatment outcome; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Helicobacter Infections; Helicobacter pylori; Homeodomain Proteins; Humans; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Phenotype; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Time Factors; Transcription Factors; Treatment Outcome; Tumor Markers, Biological | - |
dc.title | Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/modpathol.2013.229 | - |
dc.identifier.pmid | 24390222 | - |
dc.identifier.scopus | 2-s2.0-84905504436 | - |
dc.relation.pages | 1116-1125 | - |
dc.relation.journalvolume | 27 | - |
dc.relation.journalissue | 8 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Pathology | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0001-5042-0503 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。